Strategic leadership With recent executive leadership changes including a new Chairman and CEO and a strategic President, there is momentum for targeted partnerships and high-level outreach to drive collaborations in electrophysiology and adjacent therapies.

Funding momentum Significant recent financing and a high‑profile Series C funding round signal investor confidence and a potential window for co‑developed ventures, joint ventures, or sponsored pilots with larger medical device companies.

Non-thermal niche CENTAURI delivers pulsed electric field ablation that minimizes muscle stimulation and gaseous emboli, presenting a differentiator for hospitals and clinics seeking safer, energy‑efficient ablation options to treat cardiac arrhythmias.

Regulatory & market gaps CENTAURI is not US‑sold yet, indicating a market entry opportunity for distributors, regional partners, or collaboration with US players to navigate regulatory pathways and establish adoption in key cardiology centers.

Ecosystem fit Compatibility with select focal‑ablation catheters and mapping systems suggests potential for integration with established device ecosystems; engage with major electrophysiology platforms and KOLs to co‑develop compatible workflows.